🚀 VC round data is live in beta, check it out!
Salubris Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Salubris Pharmaceuticals and similar public comparables like Baxter International, Abivax, Fosun Pharma, Praxis Precision Medicines and more.
Salubris Pharmaceuticals Overview
About Salubris Pharmaceuticals
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalosporins, and bone resorption inhibitors. Its products mainly focus on the areas of cardio-cerebral vascular disease, diabetes, complications, anti-tumor, and orthopedics. Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.
Founded
2007
HQ
Employees
3.6K
Website
Financials (LTM)
EV
$9B
Salubris Pharmaceuticals Financials
Salubris Pharmaceuticals reported last 12-month revenue of $688M.
In the same LTM period, Salubris Pharmaceuticals generated $515M in gross profit and $104M in net income.
Revenue (LTM)
Salubris Pharmaceuticals P&L
In the most recent fiscal year, Salubris Pharmaceuticals reported revenue of $588M and EBITDA of $177M.
Salubris Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $688M | XXX | $588M | XXX | XXX | XXX |
| Gross Profit | $515M | XXX | $427M | XXX | XXX | XXX |
| Gross Margin | 75% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | — | XXX | $177M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 30% | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $104M | XXX | $88M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 15% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Salubris Pharmaceuticals Stock Performance
Salubris Pharmaceuticals has current market cap of $10B, and enterprise value of $9B.
Market Cap Evolution
Salubris Pharmaceuticals' stock price is $8.61.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9B | $10B | -3.0% | XXX | XXX | XXX | $0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSalubris Pharmaceuticals Valuation Multiples
Salubris Pharmaceuticals trades at 13.7x EV/Revenue multiple, and 53.2x EV/EBITDA.
EV / Revenue (LTM)
Salubris Pharmaceuticals Financial Valuation Multiples
As of April 19, 2026, Salubris Pharmaceuticals has market cap of $10B and EV of $9B.
Equity research analysts estimate Salubris Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Salubris Pharmaceuticals has a P/E ratio of 92.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10B | XXX | $10B | XXX | XXX | XXX |
| EV (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV/Revenue | 13.7x | XXX | 16.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 53.2x | XXX | XXX | XXX |
| EV/EBIT | 81.3x | XXX | 83.2x | XXX | XXX | XXX |
| EV/Gross Profit | 18.3x | XXX | 22.0x | XXX | XXX | XXX |
| P/E | 92.5x | XXX | 108.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 114.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Salubris Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Salubris Pharmaceuticals Margins & Growth Rates
Salubris Pharmaceuticals' revenue in the last 12 month grew by 21%.
Salubris Pharmaceuticals' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Salubris Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 2% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 38% | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 13% | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Salubris Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Salubris Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Baxter International | XXX | XXX | XXX | XXX | XXX | XXX |
| Abivax | XXX | XXX | XXX | XXX | XXX | XXX |
| Fosun Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Praxis Precision Medicines | XXX | XXX | XXX | XXX | XXX | XXX |
| Axsome Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Salubris Pharmaceuticals M&A Activity
Salubris Pharmaceuticals acquired XXX companies to date.
Last acquisition by Salubris Pharmaceuticals was on XXXXXXXX, XXXXX. Salubris Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Salubris Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSalubris Pharmaceuticals Investment Activity
Salubris Pharmaceuticals invested in XXX companies to date.
Salubris Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Salubris Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Salubris Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Salubris Pharmaceuticals
| When was Salubris Pharmaceuticals founded? | Salubris Pharmaceuticals was founded in 2007. |
| Where is Salubris Pharmaceuticals headquartered? | Salubris Pharmaceuticals is headquartered in China. |
| How many employees does Salubris Pharmaceuticals have? | As of today, Salubris Pharmaceuticals has over 3K employees. |
| Is Salubris Pharmaceuticals publicly listed? | Yes, Salubris Pharmaceuticals is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Salubris Pharmaceuticals? | Salubris Pharmaceuticals trades under 002294 ticker. |
| When did Salubris Pharmaceuticals go public? | Salubris Pharmaceuticals went public in 2009. |
| Who are competitors of Salubris Pharmaceuticals? | Salubris Pharmaceuticals main competitors are Baxter International, Abivax, Fosun Pharma, Praxis Precision Medicines. |
| What is the current market cap of Salubris Pharmaceuticals? | Salubris Pharmaceuticals' current market cap is $10B. |
| What is the current revenue of Salubris Pharmaceuticals? | Salubris Pharmaceuticals' last 12 months revenue is $688M. |
| What is the current revenue growth of Salubris Pharmaceuticals? | Salubris Pharmaceuticals revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Salubris Pharmaceuticals? | Current revenue multiple of Salubris Pharmaceuticals is 13.7x. |
| Is Salubris Pharmaceuticals profitable? | Yes, Salubris Pharmaceuticals is net-income-positive (as of the last 12 months). |
| What is the current net income of Salubris Pharmaceuticals? | Salubris Pharmaceuticals' last 12 months net income is $104M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.